Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, International, Multicenter, Single-arm, Uncontrolled, Phase IIIb Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Demonstrate an Insufficient Response to Treatment With Phosphodiesterase-5 Inhibitors (PDE-5i)

NCT02007629 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02007629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02007629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, International, Multicenter, Single-arm, Uncontrolled, Phase IIIb Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Demonstrate an Insufficient Response to Treatment With Phosphodiesterase-5 Inhibitors (PDE-5i)
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
February 18, 2014
Completion date
December 29, 2016
Enrollment
61 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, pulmonary